IP Library Granted Patent US 10,117,892
Granted Patent B2
US 10,117,892 · App. 14/473,319 · Granted Nov 6, 2018

Devices and methods for reducing the appearance of cellulite

Inventors: Tracy Ann Perry (Santa Barbara, CA); Rui Avelar (Santa Barbara, CA); Justin Schwab (Santa Barbara, CA); Zachary Dominguez (Santa Barbara, CA); Edwin Kayda (Santa Barbara, CA)
Assignee: Allergan, Inc.
A61K31/728A61B17/32002A61B17/3205A61B17/3421A61K8/735A61K38/4886A61Q19/06A61B2017/00792A61B2017/320028A61B2017/3454A61K2800/91C12Y304/24003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,117,892
App. No.
14/473,319
Granted
Nov 6, 2018
Kind
B2
Abstract

Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.

Claims (13)

1. A composition useful for reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient, the composition comprising:

an injectable gel comprising:

a mixture of at least collagenase I and collagenase II in a mass ratio of 1:1, the mixture having a specific activity of at least about 500 SRC units/mg; and

at least one hyaluronic acid combined with or mixed with the collagenase I and collagenase II, the at least one hyaluronic acid present in an amount effective to provide a physical barrier between tissue planes to discourage regrowth of septal bands disrupted by the collagenase mixture: and

at least one lipolytic agent capable of causing a reduction in the fat stores of adipocytes, wherein the at least one lipolytic agent is selected from the group consisting of phosphatidylcholine, conjugated linoleic acid, deoxycholate, magnolol, and a lipolytic enzyme.

2. The composition of claim 1 , the mixture having specific activity from about 500 SRC units/mg to about 15,000 SRC units/mg.

3. The composition of claim 1 , the mixture having specific activity of at least about 700 SRC units/mg.

4. The composition of claim 1 , the mixture having specific activity of at least about 1000 SRC units/mg.

5. The composition of claim 1 , the mixture having specific activity of at least about 1500 SRC units/mg.

6. The composition of claim 1 , comprising the at least one hyaluronic acid in a concentration of between about 10 mg/mL and 40 mg/mL.

7. The composition of claim 1 , wherein the at least one hyaluronic acid comprises a first and a second hyaluronic acid where the first hyaluronic acid has a higher viscosity than the second hyaluronic acid.

8. The composition of claim 1 , wherein the at least one hyaluronic acid is a crosslinked hyaluronic acid.

9. The composition of claim 8 , wherein the at least one hyaluronic acid is crosslinked with a crosslinker selected from the group consisting of glutaraldehyde (GTA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 1,4-butanediol diglycidyl ether (BDDE), and divinyl sulfone (DVS).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2018
From: PERRY, TRACY ANN; AVELAR, RUI; SCHWAB, JUSTIN; DOMINGUEZ, ZACHARY
To: ALLERGAN, INC.
Reel/Frame 046819/0437 →
Continuity (4)
Provisional Application 61871600 · Aug 29, 2013
Provisional Application 61871698 · Aug 29, 2013
Provisional Application 61874853 · Sep 6, 2013
Related Publication 20150064165A1 · Mar 5, 2015
Cited By (4)
US 12,527,594 US 12,527,597 US 12,697,132 US 12,702,473